“Virtual” Companies, Real Responsibilities: Navigating Compliance When Partnering with Contract Development and Manufacturing Organizations (CDMOs)

Recorded June 10, 2026 | 12:30PM–2:00PM ET | Live Webinar

Overview

“Virtual” Companies, Real Responsibilities: Navigating Compliance When Partnering with Contract Development and Manufacturing Organizations (CDMOs)

The rise of “virtual” companies has created confusion about regulatory obligations when partnering with Contract Development and Manufacturing Organizations (CDMOs), particularly for makers of OTC drugs, dietary supplements, cosmetics, and combination products. This webinar will examine the legal manufacturer responsibilities these companies retain, with a focus on supplier qualification, quality agreements, change control, and product specifications. It will also explore the role of Private Label Distributors (PLDs) in ensuring compliance with applicable cGMP requirements, labeling controls, and complaint handling. The panel will also highlight common pitfalls observed in FDA 483s and warning letters. Join FDA compliance experts and industry veterans as they discuss practical strategies for maintaining effective oversight, avoiding enforcement actions, and ensuring product quality and consumer safety.

$149

Members

$249

Non-Members

Speakers

Donald Ashley
Read Bio
Principal, Regulatory Compliance, ELIQUENT Life Sciences

Shelly
Read Bio
Sr. Director, Dietary Supplement and Tobacco Consulting Services, EAS Consulting Group

Christina Siniscalchi
Read Bio
Chief Quality Officer, Alvogen

James Wabby
Read Bio
Head, Regulatory Affairs—Combination Products and Emerging Technologies, AbbVie

FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals also may be honored by other states. The CLE credits will be posted as they are granted and registrants can request to be notified when approval is received.